Every success story starts the same way: with an idea. Whether those behind the idea enjoy early success or face setbacks along the way, innovators believe their work will ultimately help drive society forward. Take the likes of Apple or Tesla; without a certain degree of tenacity and determination, their impact on the global community may have not been as significant. The same is also true for mRNA vaccine developers.
Though the field is still relatively young, the early efforts of academics and companies driving progress have captured global attention. In our mRNA eBook, we cut through the hype, buzz, and all-too-frequent misinformation to take stock of mRNA’s successes, and look ahead to future challenges. Kicking off with a retrospective, we review three moments that defined the COVID-19 pandemic in 2021. After all, it’s hard to talk about mRNA without talking about the pandemic!
Next up we have a wider view of mRNA’s vaccine potential in our interview with Sartorius’ Head of Market Entry Strategy for Viral Based Therapeutics, Amélie Boulais, on the manufacturing challenges that mRNA vaccines face.
We also have input from Bellal Moghis of Agilent, who lays out his four gems of advice for best practice in mRNA sequencing, and also from Evelina Angov on how mRNA could help to turn the tables on malaria.
The eBook also features an interview with CureVac Chief Scientific Officer Igor Splawski. “Most mRNA trials before COVID-19 involved only a small number of individuals,” notes Splawski. “Now, millions have been vaccinated with mRNA.”
The future is already here, so hit the orange button below and read up!
Supported by
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
